MDM2 and cancer: TP53 mutations have been found in approximately half of the human cancers, while wild-type p53 in the rest of the malignancies are often functionally inactivated because of the overexpressed negative regulators mouse double minute 2 (MDM2) and mouse double minute X (MDMX).5